Who Owns Accuray Company?

Accuray Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Accuray?

Accuray Incorporated, a leader in radiation oncology, became a publicly traded entity in February 2007. Its journey began with a vision to revolutionize cancer treatment through advanced technology.

Founded in 1990, Accuray's innovative spirit is rooted in its development of precise radiosurgery systems. The company's commitment to improving patient care is evident in its technological advancements.

Understanding Accuray's ownership is key to grasping its strategic direction. As of fiscal year 2024, the company reported revenues of approximately $447.6 million, underscoring its significant presence in the global market. Its systems are utilized in around 50 countries, showcasing its international reach and impact. The evolution of its ownership, from its inception to its current institutional and public shareholders, provides insight into its corporate governance and future trajectory. This includes the impact of its pioneering Accuray BCG Matrix on its market positioning.

Accuray Incorporated's journey began in 1990, founded by Dr. John R. Adler, Jr., a distinguished professor at Stanford University. Initially established as NeuroControl Corporation, the company was rebranded to Accuray Incorporated in 1992, driven by Dr. Adler's ambition to bring a revolutionary robotic radiosurgery system to the medical field.

Founding Vision

Dr. John R. Adler, Jr., a pioneer in neurosurgery and radiation oncology, envisioned a future where robotic precision could transform cancer treatment.

Early Name

The company was initially founded as NeuroControl Corporation before adopting the name Accuray Incorporated in 1992.

Core Technology

Accuray's foundational goal was the commercialization of its groundbreaking robotic radiosurgery system, a vision that materialized with the first patient treatment in 1994.

Key Early Investor

Dr. James Doty, a fellow neurosurgeon and colleague of Dr. Adler, was a crucial early investor and played a vital role in securing funding and restructuring the company.

Financial Support

When facing financial challenges, the company received critical support from a venture firm in Taiwan, facilitated by Dr. Doty's efforts.

Philanthropic Contribution

Dr. James Doty's dedication extended to donating all of his Accuray stock, valued at $29 million, to charitable causes.

The early days of Accuray were characterized by a strong focus on innovation, with the company's founding team dedicated to advancing the field of robotic radiosurgery. This commitment was validated in 1994 when the first patient was treated using the CyberKnife System, marking a significant milestone in the company's history and its pursuit of cutting-edge medical technology. Understanding the Brief History of Accuray provides context for its current ownership structure and strategic direction.

Accuray SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Accuray Incorporated became a publicly traded entity on February 8, 2007, through its Initial Public Offering on the NASDAQ Global Market. This event marked a significant shift in its ownership structure, transitioning from private to public hands.

Following its IPO, Accuray's ownership has diversified, with institutional investors comprising the largest segment of shareholders. This distribution is characteristic of established public companies in the medical device sector, often indicating investor confidence. While precise current ownership percentages are not publicly detailed in all reports, regulatory filings such as those with the SEC provide a comprehensive view of Accuray stock ownership. Understanding the Target Market of Accuray can also provide context for its investor base.

Accuray's Ownership Landscape

Accuray's ownership structure is primarily held by institutional investors, reflecting broad market confidence in the company's operations and future prospects.

• Accuray became a publicly traded company in 2007.
• Institutional investors are the dominant Accuray shareholders.
• The company's financial health in fiscal year 2024 included $64.0 million in cash and equivalents.
• Changes in major shareholder holdings can influence Accuray's corporate governance and strategic direction.
• Accuray's stock performance is often linked to the activities of its significant investors.

Accuray PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The strategic direction and operations of Accuray Incorporated are overseen by its executive leadership team and Board of Directors. As of late 2024, Suzanne Winter serves as President and Chief Executive Officer and is also a director. Other key executive figures include Ali Pervaiz as Executive Vice President and Chief Financial Officer, and Franco N. Palomba as Executive Vice President, Global Operations & OUS Commercial.

The Accuray company ownership structure is that of a publicly traded entity, meaning its stock is available for purchase by the general public and institutional investors. While the provided information details the current Board of Directors, it does not explicitly identify individuals or entities holding significant voting power due to founder status or special share classes. Accuray operates under the regulatory framework of the SEC, which typically mandates a one-share-one-vote principle for common stock. Understanding the Marketing Strategy of Accuray can provide context for how management aims to increase shareholder value, which in turn can influence Accuray stock ownership patterns.

Accuray's Corporate Governance

Accuray's Board of Directors comprises individuals with diverse expertise. The company operates as a public entity, subject to SEC regulations.

• Board members bring varied backgrounds, including advisory and executive experience.
• Suzanne Winter is the current President and CEO.
• The board composition reflects a mix of industry and medical professionals.
• Specific details on major shareholder representation on the board are not publicly detailed.

Accuray Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent years have seen shifts in Accuray's operational focus and strategic alliances, influencing its ownership landscape. The company has actively pursued technological advancements and market expansion, particularly within the precision radiation oncology sector.

Accuray Incorporated has been actively engaged in strategic partnerships and technological development over the past three to five years. A notable joint venture in Tianjin, China, received its operating license in July 2019. In 2022, a collaboration with Limbus AI Inc. aimed to enhance adaptive radiotherapy through AI-driven auto contouring algorithms. Financially, for the fiscal year ending June 30, 2024, Accuray reported total net revenue of $446.6 million, with a GAAP net loss of $15.5 million and Adjusted EBITDA of $19.7 million. The first quarter of fiscal year 2025 (ended September 30, 2024) saw total net revenue of $101.5 million and a net loss of $4.0 million. The company has raised its fiscal year 2025 revenue guidance to between $463 million and $475 million, with Adjusted EBITDA projected between $28.5 million and $31.0 million. As of December 31, 2024, the order backlog stood at $463.1 million. Accuray is scheduled to report its fourth quarter fiscal 2025 financial results on August 13, 2025. The company's public listing in 2007 has led to a broader ownership distribution. Understanding the Competitors Landscape of Accuray can provide context for its market position and ownership trends.

Accuray's Financial Outlook

Accuray has projected increased revenue for fiscal year 2025. The company anticipates Adjusted EBITDA to be in the range of $28.5 million to $31.0 million.

Strategic Partnerships and Growth

Key partnerships, including one in China, highlight Accuray's focus on market penetration. Technological advancements in areas like AI-driven radiotherapy are central to its growth strategy.

Order Backlog Strength

The company's order backlog reached $463.1 million as of December 31, 2024. This indicates a solid pipeline of future business for Accuray.

Ownership Trends Overview

Industry trends suggest increased institutional ownership, a common pattern for publicly traded companies. Accuray's ownership structure reflects this broader market dynamic.

Accuray Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔